Screener
MapLight Therapeutics, Inc. MPLT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $55,707 | $46,729 |
| Short-term investments | 254,406 | 258,374 |
| Prepaid expenses and other current assets | 17,115 | 19,567 |
| Total current assets | 327,228 | 324,670 |
| Property and equipment, net | 968 | 1,095 |
| Long-term investments | 85,090 | 147,993 |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s cash & equivalents?
- MapLight Therapeutics, Inc. (MPLT) reported cash & equivalents of $55.71M in Q1 2026.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about MapLight Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude